LVW Advisors
NKTR icon

LVW Advisors’s Nektar Therapeutics NKTR Stock Holding History

LVW Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$207K Buy
3,412
+390
+13% +$27.4K 0.02% 444
2026
Q2 		$211K Hold
3,022
– – 0.02% 441
2026
Q1 		$217K Buy
+3,022
New +$172K 0.02% 399

Other funds holding NKTR

Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Iridian Asset Management
Iridian Asset Management Westport, Connecticut $275M AUM 37.66% 1-Year Est. Return
Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
HB Wealth Management
HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return
FNY Investment Advisers
FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
Leonteq Securities AG
Leonteq Securities AG Zurich, Switzerland $2.44B AUM 50.17% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

LVW Advisors's NKTR Position: Q3 2026 in Review

LVW Advisors increased its Nektar Therapeutics (NKTR) stake by 13% in Q3 2026, buying an estimated $27.4K and bringing the position to 3,412 shares worth $207K. The position accounts for 0.02% of the portfolio, ranked #444.

LVW Advisors first reported a position in NKTR in Q1 2026 and has held it in 3 quarters since. The position peaked at $217K in Q1 2026. 32 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.

  • LVW Advisors held 3,412 shares of Nektar Therapeutics worth $207K as of Q3 2026.
  • LVW Advisors bought 390 Nektar Therapeutics shares in Q3 2026, an estimated $27.4K.
  • Nektar Therapeutics made up 0.02% of LVW Advisors's portfolio in Q3 2026, its #444 holding.
  • LVW Advisors first reported a position in Nektar Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • LVW Advisors's Nektar Therapeutics position peaked at $217K in Q1 2026.
  • 32 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.

Based on LVW Advisors's 13F filing for Q3 2026, filed 19 Oct 2026.